#1 Clinical Trials Search in Europe

Pemetrexed

Pemetrexed, also known by its brand name Alimta, is a chemotherapy drug being studied in various clinical trials for its effectiveness in treating different types of cancer. This article explores how pemetrexed is being used in clinical research to potentially improve outcomes for patients with lung cancer, mesothelioma, gastric cancer, and other solid tumors.

Table of Contents

Overview of PEMETREXED

PEMETREXED is a chemotherapy drug used to treat certain types of cancer. It is also known by the brand name Alimta[1]. PEMETREXED works by blocking enzymes that cancer cells need to grow and multiply[5]. It belongs to a class of drugs called antimetabolites or antifolates[5].

Other names for PEMETREXED include:[5]

  • LY231514
  • MTA
  • Multitargeted Antifolate
  • NSC-698037

Uses and Conditions Treated

PEMETREXED is primarily used to treat the following conditions:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer. PEMETREXED is used for advanced NSCLC, including metastatic (spread to other parts of the body) NSCLC[1][2].
  • Malignant pleural mesothelioma: This is a rare cancer that affects the lining of the lungs. PEMETREXED is used in combination with cisplatin to treat this condition[5].

PEMETREXED may be used as a first-line treatment (initial treatment) or after other treatments have been tried[1][5].

How PEMETREXED is Given

PEMETREXED is typically administered in the following way:

  • Given through an intravenous (IV) infusion into a vein
  • Usually given once every 3 weeks (21-day cycle)
  • The infusion typically takes about 10 minutes[1][4]
  • The dose is usually 500 mg per square meter of body surface area[1][4]

To help reduce side effects, patients are usually given the following supplements before and during PEMETREXED treatment:[5]

  • Folic acid (vitamin B9) taken by mouth daily
  • Vitamin B12 injections every 9 weeks
  • Dexamethasone (a steroid) taken before, on the day of, and after treatment to reduce the risk of skin rash

Combination Treatments

PEMETREXED is sometimes used in combination with other cancer treatments to potentially improve effectiveness. Some combinations studied include:

  • PEMETREXED + cisplatin: For malignant pleural mesothelioma[5]
  • PEMETREXED + carboplatin: For non-small cell lung cancer[2]
  • PEMETREXED + paclitaxel + bevacizumab: An experimental combination for advanced NSCLC[4]
  • PEMETREXED + gemcitabine: Studied for head and neck cancer[3]

Side Effects and Precautions

Like all chemotherapy drugs, PEMETREXED can cause side effects. Common side effects may include:[5]

  • Fatigue
  • Nausea and vomiting
  • Loss of appetite
  • Low blood cell counts (which can increase risk of infection, bleeding, and fatigue)
  • Skin rash
  • Diarrhea or constipation

To help manage side effects, patients are closely monitored during treatment. Blood tests are done regularly to check blood cell counts. Patients may also be asked to report their symptoms using special questionnaires or websites[4].

Effectiveness and Outcomes

The effectiveness of PEMETREXED can vary depending on the type and stage of cancer, as well as individual patient factors. Some key points about its effectiveness include:

  • In advanced NSCLC, PEMETREXED has shown to improve progression-free survival (time without cancer growing) compared to some other chemotherapy regimens[2].
  • For malignant pleural mesothelioma, the combination of PEMETREXED and cisplatin is considered a standard treatment option[5].
  • Researchers continue to study PEMETREXED in various combinations and for different types of cancer to find the most effective treatments[3][4].

Frequently Asked Questions

How long do patients typically receive PEMETREXED treatment?

The duration of treatment can vary depending on how well the cancer responds and how well the patient tolerates the medication. Some patients may receive treatment for several months or even a year or more if it continues to be effective and side effects are manageable[1].

Can PEMETREXED be used for all types of lung cancer?

PEMETREXED is primarily used for non-small cell lung cancer (NSCLC), which is the most common type. It is not typically used for small cell lung cancer, which is a less common type that is treated differently[1][2].

Why are vitamin supplements given with PEMETREXED?

Folic acid and vitamin B12 supplements are given to help reduce some of the side effects of PEMETREXED, particularly those related to blood cell counts and gastrointestinal symptoms. These vitamins help support normal cell function while the chemotherapy targets cancer cells[5].

Summary Table

Aspect Details
Drug Name PEMETREXED (Alimta)
Drug Type Chemotherapy (antimetabolite/antifolate)
Main Uses Non-small cell lung cancer, Malignant pleural mesothelioma
Administration Intravenous infusion, typically every 3 weeks
Common Side Effects Fatigue, nausea, low blood counts, skin rash
Supplements Required Folic acid, Vitamin B12

Glossary

  • Antimetabolite – A type of chemotherapy drug that interferes with DNA and RNA production in cells
  • Mesothelioma – A type of cancer that develops in the lining that covers the outer surface of some of the body’s organs
  • Metastatic – Cancer that has spread from where it started to other parts of the body
  • Non-small cell lung cancer (NSCLC) – The most common type of lung cancer, accounting for about 80-85% of all cases
  • Progression-free survival – The length of time during and after treatment that a patient lives with the disease but it does not get worse

Trial sources

  • [1]: https://clinicaltrials.gov/study/NCT04166487
  • [2]: https://clinicaltrials.gov/study/NCT01639001
  • [3]: https://clinicaltrials.gov/study/NCT00589667
  • [4]: https://clinicaltrials.gov/study/NCT00807573
  • [5]: https://clinicaltrials.gov/study/NCT00508144
Aspect Details
Drug Name Pemetrexed (Alimta)
Mechanism of Action Blocks enzymes needed for cancer cell growth
Cancer Types Studied Non-small cell lung cancer, mesothelioma, gastric cancer, thymoma, thymic carcinoma, chondrosarcoma, cervical cancer
Typical Dosing 500 mg/m2 intravenously every 3 weeks
Supplementation Folic acid and vitamin B12 to reduce side effects
Common Side Effects Fatigue, nausea, loss of appetite, diarrhea, skin rash
Efficacy Measures Tumor response rate, progression-free survival, overall survival
Combination Therapies Studied with other drugs like carboplatin, bevacizumab, and nab-paclitaxel
Administration Routes Intravenous infusion, intraventricular (in some trials)
Trial Phases Phase I, II, and III studies ongoing

FAQ

  • What is pemetrexed and how does it work? Pemetrexed (Alimta) is a chemotherapy drug that works by blocking enzymes needed for cancer cell growth. It interferes with the formation of DNA and other processes that cancer cells need to divide and spread.
  • What types of cancer is pemetrexed being studied for? Clinical trials are investigating pemetrexed for various cancers including non-small cell lung cancer, mesothelioma, gastric cancer, thymoma, thymic carcinoma, chondrosarcoma, and cervical cancer.
  • How is pemetrexed typically administered in clinical trials? Pemetrexed is usually given as an intravenous infusion every 3 weeks. The typical dose is 500 mg/m2. Patients also receive folic acid and vitamin B12 supplements to help reduce side effects.
  • What are some potential side effects of pemetrexed? Common side effects may include fatigue, nausea, loss of appetite, diarrhea, and skin rash. More serious side effects can include low blood cell counts, kidney problems, and lung inflammation. Side effects are closely monitored in clinical trials.
  • How do researchers determine if pemetrexed is effective in clinical trials? Researchers look at outcomes like tumor response rate, progression-free survival, and overall survival to assess pemetrexed's effectiveness. They also evaluate safety and side effects to determine the optimal dosing and use of the drug.

Ongoing Clinical Trials on Pemetrexed

  • Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Spain

  • A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland Spain

  • A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Italy The Netherlands +3

  • Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Greece Hungary +6

  • Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Greece Italy Poland +3

  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +11

  • A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

    Recruiting

    3 1 1
    Investigated drugs:
    Czechia France Germany Greece Hungary Italy +2

  • Study of STK-012 Alone and Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Ireland Italy Poland Spain

  • A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Greece Italy Poland Romania

Glossary

  • Pemetrexed: A chemotherapy drug that works by blocking enzymes needed for cancer cell growth and division. Also known by the brand name Alimta.
  • Clinical trial: A research study that tests how well new medical approaches work in people. Clinical trials are used to evaluate new treatments, including drugs like pemetrexed.
  • Non-small cell lung cancer (NSCLC): The most common type of lung cancer, accounting for about 80-85% of all cases. Several clinical trials are studying pemetrexed for NSCLC treatment.
  • Mesothelioma: A type of cancer that develops in the lining that covers the outer surface of some of the body's organs. Pemetrexed is approved for treating malignant pleural mesothelioma.
  • Intravenous (IV) infusion: A method of delivering medications directly into the bloodstream through a vein. Pemetrexed is typically given as an IV infusion in clinical trials.
  • Progression-free survival: The length of time during and after treatment that a patient lives with cancer without it worsening. This is often used as a measure of treatment effectiveness in clinical trials.
  • Overall survival: The length of time from the start of treatment that patients are still alive. This is an important measure of treatment effectiveness in cancer clinical trials.
  • Dose-limiting toxicity: Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose. Identifying dose-limiting toxicities helps determine the optimal dose of a drug.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors. A standard way to measure how well a cancer patient responds to treatment, used in many clinical trials.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. This helps researchers understand how a drug behaves in the body.